Effects of pentoxifylline and H-89 on epileptogenic activity of Bucladesine (cas 16980-89-5) in pentylenetetrazol-treated mice

Add time:08/05/2019    Source:sciencedirect.com

The present study shows interactive effects of pentoxifylline (PTX) as a phosphodiesterase (PDE) inhibitor, H-89 as a protein kinase A (PKA) inhibitor and Bucladesine (cas 16980-89-5) (db-cAMP) as a cAMP agonist on pentylenetetrazol (PTZ)-induced seizure in mice. Different doses of pentoxifylline (25, 50, 100 mg/kg), bucladesine (50, 100, 300 nM/mouse), and H-89 (0.05, 0.1, 0.2 mg/100 g) were administered intraperitoneally (i.p.), 30 min before intravenous (i.v.) infusion of PTZ (0.5% w/v). In combination groups, the first and second components were injected 45 and 30 min before PTZ infusion. In all groups, the control animals received an appropriate volume of vehicle. Single administration of PTX had no significant effect on both seizure latency and threshold. Bucladesine significantly decreased seizure latency and threshold only at a high concentration (300 nM/mouse). Intraperitoneal administration of H-89 (0.2 mg/100 g) significantly increased seizure latency and threshold in PTZ-treated animals. All applied doses of bucladesine in combination with PTX (50 mg/kg) caused a significant reduction in seizure latency. Pretreatment of animals with PTX (50 and 100 mg/kg) attenuated the anticonvulsant effect of H-89 (0.2 mg/100 g) in PTZ-exposed animals. H-89 (0.05, 0.2 mg/100 g) prevented the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold. In conclusion, we showed that seizure activities were affected by pentoxifylline, H-89 and bucladesine via interactions with intracellular cAMP and cGMP signaling pathways, cyclic nucleotide-dependent protein kinases, and related neurotransmitters.

We also recommend Trading Suppliers and Manufacturers of Bucladesine (cas 16980-89-5). Pls Click Website Link as below: cas 16980-89-5 suppliers

Prev:On the nature of the phenylazo group
Next:The quantitative evaluation of cholinergic markers in spatial memory improvement induced by nicotine–Bucladesine (cas 16980-89-5) combination in rats)